
HPV Vaccine Post-Surgery Cuts Viral Persistence
The administration of the human papillomavirus nonavalent (9vHPV) vaccine after a surgical treatment for low- and high-grade cervical intraepithelial neoplasia resulted in a significant reduction in the proportion of women positive for HPV over the 15-month study period.
METHODOLOGY:
Researchers conducted a retrospective study to examine the effectiveness of the 9vHPV vaccine after surgical treatment in women with cervical intraepithelial neoplasia.
They included 326 women (mean age, 40.7 years) who underwent carbon dioxide laser ablation for low-grade cervical intraepithelial neoplasia (CIN1) or the loop electrosurgical excision procedure for high-grade lesions (CIN2-3) between 2020 and 2024 at a centre in Italy.
Participants were divided into two groups: Vaccinated (n = 222) and unvaccinated (n = 104) groups; the vaccinated group received the 9vHPV vaccine either before surgery or within 30 days post-surgery.
Patients were followed up at 6 and 15 months post-treatment; HPV test results and colposcopy findings were analysed to determine the effect of vaccination on viral clearance.
TAKEAWAY:
During the 6-month follow-up period, HPV positivity rates were significantly lower for patients with CIN1 in the vaccinated group than for those in the unvaccinated group (18% vs 38%; P = .0169). The findings were consistent at the 15-month follow-up.
= .0169). The findings were consistent at the 15-month follow-up. During the 15-month follow-up period, HPV positivity rates were significantly lower for patients with CIN2-3 in the vaccinated group than for those in the unvaccinated group (8% vs 18%; P = .0353).
= .0353). Vaccination showed a significant effect in reducing HPV positivity among women aged 40 years or older with CIN1 ( P = .0100).
= .0100). At the end of the follow-up, post-treatment colposcopy findings were comparable between the groups, regardless of vaccination status.
IN PRACTICE:
"A comprehensive approach to cervical cancer prevention — including primary prevention (prophylactic vaccination), secondary prevention (cervical screening), and tertiary prevention (therapeutic interventions and post-treatment vaccination) — could play a crucial role in accelerating the elimination of cervical cancer worldwide," the authors wrote.
SOURCE:
This study was led by Mario Palumbo, School of Medicine, University of Naples "Federico II," Naples, Italy. It was published online on April 19, 2025, in the European Journal of Obstetrics & Gynecology and Reproductive Biology .
LIMITATIONS:
This study was limited by its retrospective observational study design.
DISCLOSURES:
This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors reported having no conflicts of interest or personal relationships that could have influenced the study.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified individual.


Health Line
9 hours ago
- Health Line
Dupuytren's Contracture Progression: What It Looks Like
Dupuytren contracture can appear as painless lumps or nodules under the skin of your hand, but progression over time can cause your fingers to curl in toward your palm. Dupuytren contracture is a medical condition affecting the palmar fascia of your hand. Fascia is a thin layer of connective tissue found throughout the body. It provides support and protection for your muscles, bones, nerves, and vessels. In your hand, the palmar fascia is the main layer of fascia in your palm, located just under your skin. It spreads out in an upside-down triangle from the base of your fingers to your wrist. Dupuytren contracture causes an atypical thickening in the palmar fascia and leads to the formation of rigid, fibrous cords. These thickened areas restrict the natural movement and function of the fascia and can pull your fingers into a bent position. Not every person diagnosed with Dupuytren contracture will develop a finger curl. The condition follows a path of progression, but it doesn't always lead to severely bent fingers. For some people, Dupuytren contracture might never progress beyond the lump or nodule phase. The progression of Dupuytren contracture Several grading and staging systems have been used to track the progression of Dupuytren contracture since the early 1950s, but there's still no universally accepted standard for classification. Doctors typically use three clinical stages to describe a diagnosis, but they may also refer to a staging system first developed in 1968 known as the Tubiana classification. Who is at risk for Dupuytren contracture? Around 80% of Dupuytren contracture is attributed to genetics, with many genes contributing in small ways to the overall risk. People of Northern European descent have a higher risk for Dupuytren contracture, and the condition has also been associated with: smoking diabetes alcohol aging low body mass index (BMI) How is Dupuytren contracture treated? Doctors treat Dupuytren contracture based on its severity. In its earliest stage, it might not require treatment if it isn't causing any pain or affecting the function of your hand. As Dupuytren contracture progresses, doctors consider: Needle aponeurotomy: A minimally invasive procedure that uses a needle to break apart thickened areas of fascia. Collagenase injections: The injections of an enzyme that dissolves collagen in Dupuytren cords. Fasciectomy: The surgical removal of affected parts of the fascia. Dupuytren contracture can't be cured, but treatments can help restore and maintain your hand's function. The takeaway Dupuytren contracture occurs when the fascia in your hand starts to thicken and constrict. In its early stages, it can appear as lumps under the skin, puckering, or hard nodules. Over time, Dupuytren contracture can progress to a point where it curls your fingers in toward your palm. Not everyone will need treatment for this condition if it doesn't cause pain or affect hand function. When treatment is necessary, nonsurgical and surgical options are available.